<DOC>
	<DOCNO>NCT01011517</DOCNO>
	<brief_summary>The investigator seek evaluate effect muscadine grape seed supplementation brachial diameter flow-mediated vasodilator response subject , risk cardiovascular disease . Methods : In randomize , double-blind , placebo-controlled crossover trial , 50 adult ( 25 men , 25 woman ) one cardiac risk factor randomize muscadine grape seed ( MGS ) supplement 1300mg daily vs.. placebo 4 week , 4-week washout study period . Resting diameter endothelial function measure use brachial flow-mediated dilation ( FMD ) determine begin end study period .</brief_summary>
	<brief_title>Muscadine Grape Seed Supplementation Vascular Function</brief_title>
	<detailed_description>Study Participants Participants adult male non-pregnant female outpatient age 18-65 one follow cardiovascular risk factor : hypertension ( blood pressure ≥ 140/90 current treatment hypertension ) ; dyslipidemia ( total cholesterol &gt; 220 mg/dL + LDL cholesterol &gt; 130 mg/dL , current use lipid-lowering medication ) ; control type 2 diabetes mellitus ( glycated hemoglobin &lt; 8.0 % without medication ) . Subjects history coronary artery disease ( history myocardial infarction coronary revascularization ) also eligible participation . Subjects exclude history congestive heart failure ( classification ) , unstable angina acute coronary syndrome within last 30 day , uncontrolled hypertension ( blood pressure ≥ 170/100 mm/Hg ) , type 1 diabetes mellitus , uncontrolled type 2 diabetes mellitus ( HbA1C ≥ 8.0 % ) , history gastrointestinal disease surgery affect absorption , peripheral arterial disease , diagnosis active cancer ( exclude squamous cell basal cell skin cancer ) , current use long-acting nitrate compound isosorbide dinitrate nitroglycerin , recent change medication ( last 30 day ) , active plan change diet exercise pattern , history hypersensitivity compound intervention placebo , history intolerance nitrate . Study Design The study double-blind , randomize crossover design evaluate effect muscadine grape seed supplementation ( Nature 's Pearl 650 mg , two capsule daily . ) The phytochemical profile supplement present Table 1 . The trial consist screen visit follow baseline closeout visit two study treatment period ( 4 week ) , separate 4-week washout period ( total 5 visit 14 week ) .Endothelial function assess begin end study period use brachial artery flow-mediated dilation ( brachial FMD - described ) . A fasting blood sample obtain open close study period measurement lipid , inflammatory marker , marker antioxidant capacity oxidative stress . Participants ask abstain red wine , antioxidant vitamin supplement ( include vitamin E , vitamin C , beta-carotene supplement , 1 cup black green tea daily , grape seed supplement . Multivitamin supplement permit long take study duration . Endothelial Function Study Protocol Details brachial FMD protocol , automate analysis reproducibility publish previously { Herrington 2001 } . Briefly , subject rest quiet , temperature-controlled room 15 minute . A standard ( pediatric ) cuff place right forearm 2 inch ( 5 cm ) antecubital fossa . Once transducer position establish left brachial artery , continuous scan brachial artery obtain 2 minute cuff occlusion , 4 minute cuff occlusion , 2 minute immediately cuff release . Data analyze automate analysis system determine change brachial artery diameter 2 minute cuff release . Statistical Analysis The effect supplementation muscadine grape seed placebo compare use pair t-tests mixed linear model take account treatment order period effect . The mixed linear model also use formally test residual effect treatment subject receive active treatment first treatment period . Stratified analysis perform look evidence differential effect age , gender , prevalent heart disease heart disease risk factor . Nominal 2-tailed p-values present primary outcome ( percent change brachial diameter ) secondary outcome . All analysis perform use SAS v. 9.1 ( Cary , NC ) .</detailed_description>
	<criteria>adult male nonpregnant female outpatient , hypertension ( blood pressure ≥ 140/90 current treatment hypertension ) , dyslipidemia ( total cholesterol &gt; 220 mg/dL + LDL cholesterol &gt; 130 mg/dL , current use lipidlowering medication ) , control type 2 diabetes mellitus ( glycated hemoglobin &lt; 8.0 % without medication ) . history congestive heart failure ( classification ) unstable angina acute coronary syndrome within last 30 day , uncontrolled hypertension ( blood pressure ≥ 170/100 mm/Hg ) , type 1 diabetes mellitus , uncontrolled type 2 diabetes mellitus ( HbA1C ≥ 8.0 % ) , history gastrointestinal disease surgery affect absorption , peripheral arterial disease , diagnosis active cancer ( exclude squamous cell basal cell skin cancer ) , current use longacting nitrate compound isosorbide dinitrate nitroglycerin , recent change medication ( last 30 day ) , active plan change diet exercise pattern , history hypersensitivity compound intervention placebo , history intolerance nitrate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>muscadine grape</keyword>
	<keyword>endothelial function</keyword>
</DOC>